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HIGHLIGHTS
• Preliminary results of this work were presented at the 2016 Academic Surgical
Congress, Jacksonville (FL), February 2–4 2016 (Original title: Selective Smo-Inhibition
Interferes With Cellular Energetic Metabolism In Colorectal Cancer)
• This study was funded by “Sapienza—University of Rome” (Funds for young
researchers) and “AIRC” (Italian Association for Cancer Research)
• Hedgehog inhibitor was kindly provided by Genentech, Inc.®.
Colon Cancer (CC) is the fourth most frequently diagnosed tumor and the second leading
cause of death in the USA. Abnormalities of Hedgehog pathway have been demonstrated
in several types of human cancers, however the role of Hedgehog (Hh) in CC remain
controversial. In this study, we analyzed the association between increased mRNA
expression of GLI1 and GLI2, two Hh target genes, and CC survival and recurrence
by gene expression microarray from a cohort of 382 CC patients. We found that patients
with increased expression of GLI1 showed a statistically significant reduction in survival.
In order to demonstrate a causal role of Hh pathway activation in the pathogenesis
of CC, we treated HCT 116, SW480 and SW620 CC cells lines with GDC-0449, a
pharmacological inhibitor of Smoothened (SMO). Treatment with GDC-0449 markedly
reduced expression of Hh target genes GLI1, PTCH1, HIP1, MUC5AC, thus indicating
that this pathway is constitutively active in CC cell lines. Moreover, GDC-0449
partially reduced cell proliferation, which was associated with upregulation of p21 and
downregulation of CycD1. Finally, treatment with the same drug reduced migration
and three-dimensional invasion, which were associated with downregulation of Snail1,
the EMT master gene, and with induction of the epithelial markers Cytokeratin-18
and E-cadherin. These results were confirmed by SMO genetic silencing. Notably,
treatment with 5E1, a Sonic Hedgehog-specific mAb, markedly reduced the expression
of Hedgehog target genes, as well as inhibited cell proliferation and mediated reversion
toward an epithelial phenotype. This suggests the existence of a Hedgehog autocrine
Magistri et al. Hedgehog Pathway Modulates CRC Invasiveness
signaling loop affecting cell plasticity and fostering cell proliferation andmigration/invasion
in CC cell lines. These discoveries encourage future investigations to better characterize
the role of Hedgehog in cellular plasticity and invasion during the different steps of CC
pathogenesis.
Keywords: colon cancer, hedgehog pathway, SMO inhibition, EMT, cell plasticity, cell invasiveness
INTRODUCTION
In colon carcinoma (CC) as for other cancers, the understanding
of cellular and molecular mechanisms involved in tumor
progression is essential to provide the rationale for novel
therapies. According to the 2016 NCCN Panel, CC is the fourth
most frequently diagnosed tumor and the second leading cause
of death in the USA. Incidence in Italy raised from 27.06% in
1970 to 52.65% in 2010 (Ciatto, 2007). Reactivation or alteration
of molecular pathways that control cellular differentiation and
proliferation play a role in the development and progression of
both familiar and sporadic CC (Al-Sohaily et al., 2012; Bertrand
et al., 2012). Numerous studies demonstrated that chemotherapy
may be helpful both for primary and for metastatic tumors
(Nappi et al., 2016). However, the persistence of cases of local
recurrence in patients treated with current protocols impels to
study the impact of novel pathways active in CC pathogenesis.
Hh pathway plays an important role in tissue development
and organogenesis (Jiang and Hui, 2008; Rimkus et al., 2016).
However, in mature organisms, Hh pathway remains selectively
active, controlling cell proliferation and differentiation.
Hh ligands are expressed by various stromal and parenchymal
tissues and act generally in a paracrine way by binding
to the plasma membrane receptor Patched (PTCH1). Upon
binding of Hh ligands to PTCH1, the G-protein–coupled
receptor, Smoothened (SMO) is activated and promotes nuclear
translocation of GLI family of zinc finger transcription factors.
GLI activation induces the transcription of Hh target gene
products, including ubiquitous genes such as GLI1, PTCH1,
and Hh-interacting protein (HIP1) (Benvenuto et al., 2016;
Rimkus et al., 2016). This canonical Hh signaling cascade plays
a role in the normal gastrointestinal development, regulating
the differentiation of normal intestinal villi and of the adjacent
mesenchymal stromal cells. In particular, in the normal adult
gastrointestinal tract, induction of the Hh pathway protects the
differentiated epithelial cells of the villous surface at the top of the
crypts of Lieberkuhn (the structural unit of the normal colon),
counteracting the canonical Wnt signaling in the basal cells of
the crypt. In the absence of Hh ligand, PTCH1 suppresses the
activation of SMO.
Since Hh pathway is involved in the control of
proliferation/differentiation status in many tissues, it is not
surprising that Hh expression and activity are altered in tumors
(Scales and de Sauvage, 2009).
Aberrant Hh signaling, which can be achieved by mutational
inactivation of PTCH1, aberrant expression of its ligand,
constitutive activation of SMO or gene amplification of GLI-
associated transcription factors, has been implicated in the
initiation and/ormaintenance of different cancer types, including
basal cell carcinoma (BCC), lung, and brain tumors and
rhabdomyosarcoma (Gupta et al., 2010).
The involvement of Hh pathway in the pathogenesis of
CC and the potential relevance for therapy has been already
addressed by different studies. It has been demonstrated that Hh-
GLI activity in epithelial tumor cells of CC is essential for tumor
growth, recurrence and metastasis, and regulates the behavior
of human CC stem cells in vivo (Varnat et al., 2009). However,
a randomized phase II trial using a pharmacological inhibitor
of Hh failed to show an incremental benefit respect to standard
treatments in a population of previously untreated patients with
metastatic CC (Berlin et al., 2013). In spite of this, recent research
based on in vitro and in vivo experimental systems, led to
controversial results (Gerling et al., 2016; Kangwan et al., 2016;
Lee T. Y. et al., 2016; Wang et al., 2016).
The aim of the present study was to analyze whether
pharmacological inhibition of Hh pathway, and specifically of
SMO, impacts epithelial plasticity and invasiveness in different
CC cell lines, and to explore the molecular mechanisms involved.
Starting from our evidence correlating Hh pathway effectors
(i.e., GLI1 and GLI2) with CC patients survival, we first treated
CC cell lines with a pharmacological SMO inhibitor, GDC-
0449, a small molecule already approved by the US Food and
Drug Administration (FDA) for the treatment of advanced basal
cell carcinoma (BCC) (Dijkgraaf et al., 2011; Takebe et al.,
2015). In addition, we investigated the effects of SMO-specific
genetic silencing as well as 5E1, a Shh-specific Monoclonal
Antibody (mAb). Our results show that Hh pathway impacts
epithelial/mesenchymal features and invasion capability of CC
cell lines.
MATERIALS AND METHODS
Cells
Primary (HCT 116, SW480) and metastatic (SW620) human CC
cell lines were grown in DMEM supplemented with 10% FBS
(GIBCO R© Life Technology, Monza, Italy) and antibiotics. These
cellular lines were reported to express detectable levels of SMO
and GLI1 (Sun et al., 2013; Sénicourt et al., 2016; Wang et al.,
2017). MeT5A cells, a human mesothelium non-tumorigenic cell
line were grown inM199 supplemented with 10% FBS (GIBCO R©
Life Technology, Monza, Italy) and antibiotics.
RNA Extraction, Reverse Transcription
(RT), and Real-Time Polymerase Chain
Reaction (RT-qPCR)
RNA, extracted from cell cultures with ReliaPrepTM RNA
Tissue Miniprep System (Promega, Madison, WI, USA), was
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reverse transcribed with iScriptTM c-DNA Synthesis Kit (Bio-
Rad Laboratories, Inc., Hercules, CA, USA) according to the
manufacturer’s instructions. cDNAs were amplified by qPCR
reaction using GoTaq R© qPCR Master Mix (Promega, Madison,
WI, USA). The specific primer pairs are listed in Table 1. Relative
amounts, obtained with 2−1Ct method, were normalized with
respect to the housekeeping gene L32. Statistical significance was
determined with a t-test with GraphPad Prism version 5.0 (La
Jolla, CA, USA). Differences were considered significant at P <
0.05 (∗p< 0.05; ∗∗p< 0.01; ∗∗∗p< 0.001).
Antibodies and Chemicals
Monoclonal antibody against E-cadherin was from BD (Becton-
Dickinson Laboratories, Mountain View, CA). Monoclonal
antibodies against Snail1 and against GLI1 were from Cell
signaling (Danvers, MA). Monoclonal antibody against pan-
cytokeratin was from Sigma (St Louis, MO). Polyclonal
antibodies against SMO (N-19) and tubulin were from
Santa Cruz biotechnology (Dallas, USA). GDC-0449, a
Hedgehog/Smoothened pharmacological inhibitor, was a
kind gift from Genentech (South San Francisco, CA). 5E1,
Shh specific mAb was purchased by Developmental Studies
Hybridoma Bank (Iowa City, Iowa, US) (Ericson et al.,
1996).
siRNA-Mediated SMO Knockdown
200 × 103 cells were seeded on 12-well plates 24 h prior
transfection. Cells were transfected with either 40 pmol ON-
TARGETplus SMARTpool against human SMO (Dharmacon
Ref#SO-2600349G) or the same amount of ON-TARGETplus
NontargetingPool (Dharmacon Ref#D-001206-14-05) and 2µl
TABLE 1 | List of specific primer pairs for qRT-PCR used in this study.
Gene Oligonucleotide sequence
L32 FW GGAGCGACTGCTACGGAAG
L32 REV GATACTGTCCAAAAGGCTGGAA
GLI1 FW GACGCCATGTTCAACTCGATG
GLI1 REV CAGACAGTCCTTCTGTCCCCAC
PTCH1 FW GAGCAGATTTCCAAGGGGAAGG
PTCH1 REV ATGAGGAGGCCCACAACCAA
HIP1 FW AGAACTGCAAAATGTGAGCCAG
HIP1 REV CTGATCAAGAATACCTGCCCTG
MUC5AC FW CCATTGCTATTATGCCCTGTGT
MUC5AC REV TGGTGGACGGACAGTCACT
CYC D1 FW CCTCTAAGATGAAGGAGACCA
CYC D1 REV CACTTGAGCTTGTTCACCA
P21 FW GAGGAGGCGCCATGTCAGAA
P21 REV AGTCACCCTCCAGTGGTGTC
SNAIL1 FW CACTATGCCGCGCTCTTTC
SNAIL1 REV GCTGGAAGGTAAACTCTGGATTAGA
CK18 FW CTGGAGACCGAGAACCGGA
CK18 REV TCCGAGCCAGCTCGTCAT
SMO FW TGAAGGCTGCACGAATGAGG
SMO REV CTTGGGGTTGTCTGTCCGAA
Lipofectamine R© RNAiMAX Reagent from Thermo Fisher
Scientific (Waltham, MA USA) in 200 µl Optimem from
Gibco (Waltham, MA USA). 1ml of supplemented medium
per well was also added. Forty-eight hours after transfection,
knockdown efficiency was determined by RT-PCR and western
blot.
Western Blotting
Monolayers of HCT 116 cells were lysed in modified RIPA
buffer containing: 50mM Tris-HCl, pH 7.4; 1% NP-40;
0.1% SDS; 0.25% Nadeoxycholate; 150mM NaCl; 1mM
EDTA; 1mM EGTA; 1mM PMSF; 1µg/ml each of aprotinin,
leupeptin, and pepstatin; and 25mM NaF (all from Sigma).
Equal amounts of proteins were resolved by SDS-PAGE.
Proteins were transferred to nitrocellulose membranes,
probed with antibodies and detected as in Battistelli et al.
(2017).
Scratch Assay
CC cell lines were pretreated with DMSO or 1µM GDC-0449
for 24 h in culture medium until reaching 100% confluency.
A scratch wound was created on the cell surface using a
micropipette tip in low serum (0.5% FBS) culture medium to
inhibit cell proliferation. Micrographs were taken at time 0 and
24 h after the scratch. Cell devoid areas at time 0 and 24 h after the
scratch were quantified through ImageJ software (NIH, Bethesda,
MD, USA). Three independent experiments for each cell line
were performed
3-Dimensional Invasion Assay and
Immunofluorescence
3-dimensional invasion assays were performed as in Strippoli
et al. (2015). HCT 116 cells (1.5 × 105) were treated with 1µM
GDC-0449 or vehicle for 12 h and then seeded in triplicate
in Ibidi 15-well chambers and allowed to attach for 3 h. 40%
matrigel (40 µl) in serum-free medium was laid over the
cells. After 1 h, 50 µl full medium containing 20% serum
(and GDC-0449 or vehicle) was added and cells incubated
for 72 h. Cells were fixed with 4% paraformaldehyde (PFA),
permeabilized with 0.25% Triton in PBS, and stained for 12 h
with rhodamine-phalloidin (to stain F-actin) and Hoechst (to
stain nuclei) in PBS. Confocal images were captured with a
Leica SP5 fitted with a 40× oil objective. Maximum projection
images consist of 30 individual images with a z-distance of
120µm. Imaris image analysis software (Bitplane Scientific
Software) was used to create a 3D view of the same cells and
to quantify invading cells. Three independent experiments were
performed.
Statistical Analysis
Survival analysis significance was based on Logrank Test.
Statistical significance of experiments performed with cell lines
was determined with a t-test using GraphPad Prism version 5.0
(La Jolla, CA, USA). Differences were considered significant at
P < 0.05.
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RESULTS
GLI Altered Expression Correlates with
Reduced Survival in CC Patients
To determine the clinical relevance of Hh-GLI pathway in CC,
we examined the association between increased GLI mRNA
expression and CC survival by exploring gene expression data
microarray from a cohort of 382 CC patients in the cancer
genome atlas (TCGA) database (Cerami et al., 2012; Gao et al.,
2013).
Notably, patients with increased GLI1 expression showed
a statistically significant reduction in overall survival (OS)
(Figure 1) and a trend toward reduced disease-free survival
(DFS) (Figure S1A). Patients with increased GLI2 expression
showed tendency to reduced survival (Figure S1B). These
findings support a role for GLI1 and GLI2 in CC pathogenesis,
and prompted us to investigate if pharmacological inhibition of
Hh pathway could affect the proliferation or the invasive capacity
of CC cell lines.
GDC-0449 Limits Cellular Proliferation of
Several CC Cell Lines
We analyzed whether treatment with GDC-0449 affects the
expression of Hh pathway specific genes in CC lines. We
exposed HCT 116, SW480, primary CC lines, and SW620, a
metastatic CC cell line, to GDC-0449 for 24 h at a concentration
(1µM) that is compatible with cellular viability. As shown in
Figures 2A–D, treatment with GDC-0449 significantly reduced
the expression of GLI1, PTCH1, HIP1, and MUC5AC, four of the
known Hh target genes, thus demonstrating that Hh pathway is
constitutively active in all three cell lines. GLI1 protein expression
upon treatment with GDC-0449 was shown in Figures S2A–C.
Raw data of the original western blots shown in this study are
displayed in Figures S5–S7.
Similar results were obtained by genetically silencing SMO,
and by using 5E1, a mAb specifically binding to Shh
(Figures 2E,F). The extent of SMO knockdown at mRNA level
is shown in Figure S3A. Notably, the efficacy of 5E1 mAb, in the
absence of exogenous stimulation, suggests the existence of an
autocrine loop maintaining Hh pathway constitutively active in
these cells.
Conversely in the MeT5A cell line, a non-tumorigenic
mesothelium cell line, the same genes were found not responsive
to the treatment with GDC-0449, therefore suggesting that these
cells do not maintain a constitutively active SMO-GLI pathway
(Figure S3B).
In order to evaluate the effect of SMO inhibition on cell
proliferation, we exposed HCT 116, SW480, SW620, and MeT5A
cells, to GDC-0449 for 24–48 h. At the concentration of 1µM,
GDC-0449 significantly inhibited cell proliferation in HCT 116,
SW480, and SW620 while causing negligible effect in MeT5A
cells (Figures 3A–D.) At the molecular level, treatment with
GDC-0449 reduced the expression of cell cycle promoters (Cyclin
D1) while inducing the expression of cell cycle inhibitors (p21) in
all of the three CC lines analyzed (Figures 3E,F). Accordingly,
both genetic silencing of SMO and treatment with 5EI mAb
led to a reduction of Cyclin D1 (Figure 3G), while increasing
the expression of p21 (Figure 3H). In contrast, no significative
changes in the expression of these genes where detected when
MeT5A were treated with GDC-0449 at the same concentrations
(Figure S3C). These results demonstrate that activation of Hh
pathway delivers proliferative signals in CC cell lines.
FIGURE 1 | Kaplan-Meier survival estimate plots for increased GLI mRNA expression in CC patients. The survival estimate was analyzed in http://www.cbioportal.org
(Cerami et al., 2012; Gao et al., 2013) and is based on Colorectal adenocarcinoma TCGA provisional dataset, which is generated by http://cancergenome.nih.gov/.
The cases were set to include tumor samples with mRNA data (RNA Seq V2, n = 382 patients). The red line shows overall survival estimate for patients with increased
GLI1 expression (11% of the patients) as compared to patients with no alteration (blue line, the rest of the patients). Eight patients were missing in the survival analysis.
The threshold for altered expression was set to z-score value = 1.2 The z-score value is used to define the cut-off for patient dichotomization in the TCGA datasets
(see http://www.cbioportal.org/). The median months survival for the increased GLI1 patient group and the reference group were 47.04 and 92.67, respectively.
Survival analysis significance was based on Logrank Test. P < 0.05 was considered significant.
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FIGURE 2 | Effect of Hh inhibition on Hh pathway-induced genes. HCT 116, SW480 and SW620 were treated with DMSO vehicle (NT) or with 1µM GDC-0449 for
24 h. Expression of GLI1 (A), PTCH1 (B), HIP1 (C), MUC5AC (D) was evaluated on total RNA by qRT-PCR. Bars represent means ± SEM of 7 experiment for HCT
116 cells, three experiments for SW480 and SW620 cells. Expression of GLI1, PTCH1, HIP1, MUC5AC in HCT 116 cells transfected with either control or specific
SMO-targeting siRNAs (E). Expression of GLI1, PTCH1, HIP1, MUC5AC in HCT 116 cells treated with either isotype-control mAb or 5E1 mAB (F). Bars represent
means ± SEM of three experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
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FIGURE 3 | Effect of Hh inhibition on cell proliferation. (A) HCT 116, (B) SW480, (C) SW620 or (D) MeT5A cells were treated with vehicle (DMSO) or with GDC-0449
(1µM) for 24–48 h. Cell proliferation was evaluated through microscopic count of living cells. Three independent experiments for each cell line were performed.
Expression of Cyclin D1 (E) and p21 (F) was evaluated on total RNA by qRT-PCR. Bars represent means ± SEM of 7 experiment for HCT 116 cells, three experiments
for SW480 and SW620 cells. (G) Expression of Cyclin D1 mRNA was evaluated in HCT 116 cells transfected with either control or specific SMO-targeting siRNAs
(left), or in HCT 116 cells treated with either isotype-control mAb or 5E1 mAb (10µg/ml) (right). (H) Expression of p21 mRNA was evaluated in HCT 116 cells
transfected with either control or specific SMO-targeting siRNAs (left), or in HCT 116 cells treated with either isotype-control mAb or 5E1 mAb (10µg/ml) (right). Bars
represent means ± SEM of three independent experiments. *P < 0.05, **P < 0.01.
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FIGURE 4 | Effect of Hh inhibition on cell directed migration and on EMT-MET dynamics. (A) HCT 116 cells were treated with vehicle (DMSO) or with GDC-0449
(1µM) in culture medium supplemented with 0.5% FCS. A scratch was performed and micrographs were taken 24 h after the scratch. Wound closure rate was
quantified (right). Three independent experiments were performed. (B) HCT 116 cells were pretreated with GDC-0449 for 24 h and then overlaid with a Matrigel matrix.
Invasion was monitored over 72 h. Three-dimensional invasion was enhanced by adding 20% FCS to the wells on top of Matrigel. Cells were stained with phalloidin
(green) and Hoechst 33342 (cell nuclei, blue). Scale bar: 100µm. 3 dimensional invasion rate was quantified (right). Three independent experiments were performed.
(C,D) Effect of GDC-0449 on genes related to EMT-MET dynamics. (C) HCT 116, SW480, and SW620 cells were treated with GDC-0449 (1µM) or
(Continued)
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FIGURE 4 | DMSO for 24 h. Expression of Snail1 mRNA was evaluated on total RNA by qRT-PCR. Bars represent means ± SEM of 7 experiment for HCT 116 cells,
three experiments for SW480 and SW620 cells. (D) Expression of Snail1 and E–cadherin in cells treated as above by western blot on total protein lysates of HCT 116
cells treated as stated in the figure. Tubulin was used as a loading control. Three independent experiments were performed. Quantification of E-cadherin and Snail1
protein expression is shown below. (E) Expression of Cytokeratin 18 (CK18) mRNA from total RNA of HCT 116 cells treated as in (C). (F) Cytokeratin expression and
localization in HCT 116 cells was evaluated through immunofluorescence analysis. Nuclei were stained in blue with Hoechst. Quantification of Cytokeratin mean
intensity is shown on the right. Two independent experiments were performed. *P < 0.05, **P < 0.01.
FIGURE 5 | (A) Snail1 and (B) Cytokeratin 18 expression was evaluated on total RNA by qRT-PCR from HCT 116 cells transfected with either control or specific
SMO-targeting siRNAs (left), or from cells treated with either isotype-control mAb or 5E1 mAb (10µg/ml) (right) (n = 3). (C) Western blot showing expression of SMO,
E-cadherin, Snail1 in HCT 116 cells transfected with either control or specific SMO-targeting siRNAs. Quantification of SMO, E-cadherin and Snail1 is shown on the
left. (n = 3). (D) Western blot showing the expression of E-cadherin, Snail1 in HCT 116 cells treated with either isotype-control mAb or 5E1 mAb (10µg/ml). Tubulin
was used as loading control. E-cadherin and Snail1 quantifications are shown on the right. Bars represent means ± SEM of three independent experiments.*P <
0.05, **P < 0.01.
GDC-0449 Inhibits Cell-Directed Motility
and Invasion and Induces Met
We then analyzed whether GDC-0449 potentially inhibits tumor
invasion. In order to analyze the effect of GDC-0449 in
controlling cell directed motility, which is relevant for tumor
invasion, we performed a scratch assay. Confluent HCT 116
monolayers were pre-treated with GDC-0449 for 24 h, a scratch
was performed and the scratch closure was evaluated after 24 h.
As shown in Figure 4A, treatment with GDC-0449 significantly
limited scratch closure.
Similar results were obtained by using SW480 and SW620 cells
(Figures S4A,B). By contrast GDC-0449 treatment had no effect
on the Hh-irresponsive cell line MeT5A (Figure S4C).
Notably, the use of a 3-dimensional invasion assay onMatrigel
matrices highlighted also a reduced invasive capacity of GDC-
0449-treated HCT 116 cells (Figure 4B).
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At the molecular level, treatment with GDC-0449 markedly
reduced the expression of Snail1, a main driver of EMT and
tumor invasion, in all CC cell lines analyzed, while increasing
the expression of the typical epithelial marker E-cadherin
(Figures 4C,D). At the same time, Cytokeratin 18 (CK18)
expression was increased both at mRNA and at protein level
(Figures 4E,F). These results were confirmed by genetic silencing
of SMO and by the use of 5E1 mAb (Figures 5A–D).
These data are in accordance with a data set from CC patients
(Tables 2, 3), from the cancer genome atlas (TCGA) database
(Cerami et al., 2012; Gao et al., 2013), where increased expression
of Hh pathway genes (GLI1 and SMO) negatively correlates
with protein expression of CDH1 (E-cadherin, epithelial marker)
and positively correlate with CDH2 (N-Cadherin) and FN
(Fibronectin), mesenchymal markers.
Overall, these results demonstrate that in primary and
metastatic CC cell lines, the functional blockade of autocrine Hh
pathway leads to a reduction of cellular growth and invasion
through a reacquisition of epithelial-like features. These results
may be helpful to more completely understand the complex
biology of CC in light of future therapeutic strategies.
DISCUSSION
The involvement of Hh in CC tumorigenesis is presently object
of controversy. CC has a complex pathogenesis; during its
progression, alterations of multiple genes and pathways are
required. The observation that Hh pathway is tightly connected
with other pathways that are often abnormally activated in CC,
such as Wnt/β-catenin or Ras, strongly suggests its involvement
in the multistep process of CC pathogenesis (Brechbiel et al.,
2014). In fact, recent evidence indicates that Hh signalingmay act
in CC in autocrine, paracrine or cancer stem cell fashion (Scales
and de Sauvage, 2009).
Notably, RNA Seq analysis in 382 patients highlighted a
significative correlation between GLI1 increased expression and
reduced survival in CC patients. These data support the results
obtained by other studies (Xu et al., 2012), and prompted us to
overcome the correlative analysis in pinpointing a mechanism;
this attempt implied to inhibit Hh pathway in CC cell lines.
We first evaluated the effect of GDC-0449, a specific SMO
inhibitor, onHh signaling in three primary andmetastatic CC cell
lines. In all cells analyzed, treatment with GDC-0449 significantly
reduced the expression of four known target genes (GLI1,
PTCH1, HIP1, MUC5AC), this implying a constitutive activation
of Hh pathway. The activity of Hh pathway in CC cell lines has
been already analyzed in other studies, with controversial results
(Douard et al., 2006; Chatel et al., 2007; Alinger et al., 2009).
The observed discrepancies with some of these studies may be
explained by the different cell lines analyzed (Alinger et al., 2009)
or by the usage of semi-quantitative techniques (Chatel et al.,
2007).
In our experimental system, treatment of all three lines with
GDC-0449 also significantly reduced cell proliferation, whereas
there was no effect in a not-responsive cell line used as a negative
control.
TABLE 2 | Mean protein expression changes in CC patients with GLI1 mRNA
overexpression.
Gene Mean protein
expression
Stdev. of protein
expression
p-Value
In GLI1
high group
(n = 41)
In reference
group
(n = 333)
In GLI1
high group
(n = 41)
In reference
group
(n = 333)
FASN −0.5 0.1 0.59 0.6 0.000001046
FOXM1 −0.36 0.02 0.38 0.56 0.000001847
CCNB1 −0.77 0.02 0.9 0.78 0.000009887
CCNE1 −0.26 0.06 0.36 0.46 0.00001511
RPS6 −0.45 0.04 0.59 0.52 0.00002737
MSH6 −0.49 −0.02 0.58 0.6 0.00004738
ACACB_PS79 −0.34 0.02 0.48 0.46 0.0001271
ACACA_PS79 −0.34 0.02 0.48 0.46 0.0001271
SLC1A5 −0.63 −0.04 0.82 0.62 0.0001453
CASP7 −0.49 0.13 0.82 1.16 0.0001513
ACACA −0.43 0 0.61 0.62 0.0002158
DIRAS3 0.23 0.06 0.23 0.33 0.0003006
FN1 0.75 0.15 0.87 0.78 0.0003219
PEA15 0.28 0.07 0.3 0.31 0.0003356
COL6A1 0.73 0.08 1 0.59 0.0004711
ARID1A −0.12 0 0.19 0.27 0.0004835
CDH2 0.15 0.03 0.18 0.25 0.0005421
EIF4E −0.15 0.04 0.29 0.29 0.000731
CHEK2 −0.29 0.09 0.62 0.44 0.0009215
RPS6KA1 −0.16 0.09 0.4 0.43 0.0009856
CCNE2 −0.07 0.05 0.19 0.24 0.001171
SMAD1 −0.13 0.02 0.23 0.23 0.001174
FOXO3_PS318 0.18 −0.03 0.36 0.24 0.001343
MSH2 −0.07 0.12 0.32 0.32 0.001649
EEF2 −0.23 0.01 0.4 0.41 0.001656
ASNS −0.13 0.15 0.46 0.57 0.001962
HSPA1A 0.82 0.23 1.04 0.86 0.002055
ITGA2 −0.23 0.07 0.52 0.46 0.002136
PCNA −0.21 0.01 0.4 0.37 0.002343
CTNNB1 −1.06 −0.32 1.34 1.01 0.002551
TGM2 0.22 0.06 0.28 0.31 0.002916
RB1 −0.06 0.12 0.32 0.32 0.003076
BCL2 0.22 0.02 0.35 0.45 0.003119
ACVRL1 0.3 0.04 0.49 0.37 0.00349
ERBB3 −0.27 0.05 0.59 0.61 0.004059
BAP1 −0.32 −0.08 0.46 0.48 0.004078
RPS6KB1 −0.3 −0.08 0.43 0.37 0.004689
ANXA1 0.34 0.03 0.6 0.59 0.005383
CDH1 −0.93 −0.3 1.24 1 0.005527
CDKN1A 0.2 0.03 0.33 0.36 0.00556
BRD4 −0.42 −0.11 0.63 0.5 0.006666
STK11 0.11 0.04 0.14 0.15 0.006734
SQSTM1 −0.31 −0.02 0.59 0.52 0.006856
EIF4EBP1 −0.13 0.04 0.35 0.34 0.007095
BAK1 0.12 0.04 0.17 0.21 0.007894
NRAS 0.17 0.08 0.19 0.23 0.008201
PGR 0.23 0.11 0.24 0.31 0.008854
CDK1_PY15 −0.23 0 0.48 0.31 0.008911
MRE11A 0.15 0.04 0.23 0.17 0.009363
AR 0.18 0.06 0.27 0.26 0.0104
WWTR1 0.13 0.01 0.27 0.27 0.0138
G6PD 0.15 0.04 0.24 0.31 0.0142
TP53BP1 −0.4 −0.05 0.78 0.72 0.0145
BECN1 0.13 0.02 0.24 0.22 0.015
RBM15 −0.54 −0.11 0.98 0.62 0.0159
(Continued)
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TABLE 2 | Continued
Gene Mean protein
expression
Stdev. of protein
expression
p-Value
In GLI1
high group
(n = 41)
In reference
group
(n = 333)
In GLI1
high group
(n = 41)
In reference
group
(n = 333)
TFRC −0.35 0.02 0.84 0.85 0.0159
EIF4G1 −0.66 −0.27 0.88 0.93 0.0181
ESR1 0.19 0.07 0.28 0.36 0.0188
CLDN7 −0.63 −0.07 1.32 1.04 0.019
XRCC5 −0.27 −0.02 0.59 0.5 0.0194
TSC2 −0.32 −0.06 0.62 0.49 0.023
GAPDH −0.39 −0.06 0.81 0.74 0.0289
MS4A1 0.12 0.04 0.22 0.18 0.029
KIT 0.28 −0.07 0.88 0.9 0.0297
FOXO3 0.13 0.05 0.19 0.24 0.03
GSK3B −0.06 0.05 0.28 0.24 0.0306
GSK3A −0.06 0.05 0.28 0.24 0.0306
CCND1 0.07 −0.01 0.21 0.23 0.0366
CDKN1B 0.21 0.09 0.32 0.34 0.0376
MAPK8_PT183 0.27 0.02 0.68 0.39 0.0383
RAB11B 0.14 0.03 0.29 0.24 0.041
RAB11A 0.14 0.03 0.29 0.24 0.041
CASP8 −0.04 0.14 0.45 0.79 0.0414
YAP1 0.29 0.14 0.42 0.37 0.0445
Data was extracted from cBioPortal, Colorectal Adenocarcinoma (TCGA, Provisional),
n(patients)= 382, z-score threshold= 1.2. The patient set was the same as in the survival
analysis (see Figure 1). Protein measurements are based on antibody arrays (RPPA =
Reverse Phase Protein Array), and the table shows only those proteins with significant
p-value (p < 0.05). The z-score threshold used was the same as in the survival analysis
(see Figure 1), where z-score 1.2 resulted in the best separation of patient groups into
Gli1 mRNA overexpressing and non-overexpressing patients.
At the molecular level, cell cycle inducers (Cyclin D1) were
decreased, whereas cell cycle blockers (p21) were increased.
Therefore, the use of GDC-0449 directly impacts cellular
proliferation and potentially tumor growth. These results were
confirmed by performing SMO genetic silencing and by using
a 5E1 Shh-specific inhibitory mAb. The effect observed using
5E1 presupposes the existence of an autocrine activatory loop
involving Shh-SMO-dependent canonical pathway activation. A
previous report analyzing loss-of-function mutation in PTCH1
suggested a role of autocrine Hh signaling in colorectal
tumorigenesis (Chung and Bunz, 2013). The autocrine loop
observed by us in CC cell lines may complement other studies
supporting a model in which paracrine Hh ligands released by
CC cells take a role in instructing the stromal components of the
tumor (Yauch et al., 2008).
Our results emphasize the role of canonical Hh signaling
in CC cell lines, although we do not exclude that other
pathways may play a role. Indeed, besides the canonical
Hh-PTCH1-SMO-driven signals, ligand-independent pathways
have been demonstrated (Merchant et al., 2004; Amakye
et al., 2013). For instance, in tumors, GLI transcription
may be decoupled from upstream Shh–PTCH1–SMO signaling
being regulated by TGF-β and KRAS (Nolan-Stevaux et al.,
2009).
Treatment with GDC-0449 also led to reduced cellular
motility in both a 2D and a 3Dmigration assays. These functional
TABLE 3 | Mean protein expression changes in CC patients with SMO mRNA
overexpression.
Gene Mean protein expression Stdev. of protein expression p-Value
In SMO
high group
(n = 54)
In reference
group
(n = 325)
In SMO
high group
(n = 54)
In reference
group
(n = 325)
RPS6KA1 −0.13 0.1 0.32 0.44 0.0001553
FN1 0.57 0.16 0.67 0.82 0.0005204
GAPDH −0.42 −0.05 0.62 0.76 0.0006319
CLDN7 −0.61 −0.06 1.08 1.07 0.002821
CASP7 −0.36 0.13 0.98 1.15 0.003758
PTEN −0.12 −0.03 0.21 0.22 0.006982
PEA15 0.21 0.08 0.29 0.32 0.008334
YAP1 0.32 0.13 0.43 0.36 0.0113
SYK −0.21 0.03 0.59 0.54 0.0138
SLC1A5 −0.36 −0.07 0.76 0.65 0.0142
TFRC −0.32 0.03 0.87 0.84 0.0172
VHL −0.59 −0.18 1.04 1.21 0.0193
LCK −0.06 0.09 0.37 0.47 0.0201
ERBB3 −0.17 0.04 0.51 0.62 0.0216
FOXO3_PS318 0.09 −0.02 0.29 0.26 0.0222
CTNNB1 −0.78 −0.34 1.15 1.05 0.0223
CDKN1B 0.2 0.08 0.32 0.34 0.0281
PECAM1 0.15 0.04 0.29 0.27 0.0282
MRE11A 0.11 0.04 0.2 0.17 0.0287
EEF2 −0.14 0 0.38 0.42 0.0304
RB1 0 0.11 0.3 0.33 0.0304
TSC2 −0.25 −0.07 0.52 0.51 0.0308
INPP4B −0.17 0.01 0.5 0.63 0.0365
RBM15 −0.4 −0.12 0.82 0.65 0.0375
AR 0.16 0.06 0.31 0.25 0.0381
EGFR −0.13 −0.05 0.21 0.25 0.0393
WWTR1 0.09 0.01 0.21 0.28 0.04
CDH1 −0.69 −0.32 1.11 1.03 0.0401
CDH2 0.1 0.03 0.2 0.25 0.0421
SMAD4 0.06 0 0.19 0.22 0.0448
SQSTM1 −0.2 −0.03 0.52 0.54 0.0451
Data was extracted from cBioPortal, Colorectal Adenocarcinoma (TCGA, Provisional),
n(patients) = 382, z-score threshold = 1.2. Protein measurements are based on
antibody arrays (RPPA = Reverse Phase Protein Array), and the table shows only those
proteins with significant p-value (p < 0.05). The z-score threshold 1.2 was selected
based on optimal separation of patient groups into SMO mRNA overexpressing and
non-overexpressing groups.
data correlated with an increased expression of epithelial
markers (E-cadherin, Cytokeratin-18) and with a significant
downregulation of Snail1, a main effector of TGF-β pathway.
With respect to cellular motility and Snail1 expression, our
results appear equally provocative in the light of the fact that
in several circumstances TGF-β facilitates tumor invasiveness
through induction of epithelial-mesenchymal transition (EMT).
EMT is a complex phenotypic conversion of epithelial cells
leading to the acquisition of a highly motile phenotype and
other mesenchymal traits, and is a key mechanism by which pre-
malignant epithelial cells acquire a highly invasive phenotype
that leads to metastatic spreading. The evidence of EMT in CC
in vivo was firstly demonstrated by Brabletz (Brabletz et al.,
2005). Subsequently, genomics studies identified EMT as a major
program in CC (Loboda et al., 2011). Moreover, expression of
EMT-related genes correlated with poorer survival in CC, but not
in other cancers (Tan et al., 2014).
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Cell migration and invasiveness are driven by actin
cytoskeleton dynamic polarization, which is controlled by
the members of the Rho GTPase superfamily Rho, Rac, and
Cdc42 (Ridley, 2015). At the same time, EMT dynamics, as well
as the acquisition of stem-like phenotypes are characterized
by selective activation of Rho GTPases (Yoon et al., 2017).
Interestingly, recent studies link Hh pathway to Rho GTPases
activation, providing potential molecular mechanisms for our
observations (Peng et al., 2017).
Hh pathway has been shown to intersect and cooperate with
other pathways by regulating the differentiation/proliferation
status of the tissue. In the intestinalmucosa, BoneMorphogenetic
Protein (BMP) and Hh pathways are preferentially activated
in differentiated layers, whereas Notch and WNT pathways
are activated in the basal cells of the crypt (Bertrand et al.,
2012). Hh controls the expression of the Notch ligand Jagged2.
Moreover, cross talks between TGF-β-induced pathways and
Hh have been demonstrated (Perrot et al., 2013). There is
evidence of an interplay between Hh and TGF-β pathways
in both normal and malignant tissues. In particular, TGF-
β may induce GLI1 expression in a GLI2-dependent manner
independently from SMO in breast cancer (Hu et al., 2008).
Furthermore, pharmacologic blockade of TGF-β signaling leads
to a reduction of GLI1 expression in cyclopamine-resistant
pancreatic adenocarcinoma (Dennler et al., 2007).
We hypothesize that in our cells Snail1 downregulation,
mediated by Hh-pathway inhibition, contributes to the
stabilization of an epithelial phenotype (underlined by the
increase in E-cadherin and Cytokeratin 18 expression). Besides
the well-known effect on tumor invasion, Snail1 downregulation
may be effective in limiting chemoresistance, as recently
demonstrated in CC (Lee T. Y. et al., 2016). Accordingly,
Hh pathway inhibition by GDC-0449 was demonstrated to
reduce the expression of a mesenchymal marker and to restore
sensitivity to 5-fluorouracil in a 5-fluorouracil-resistant CC cell
line (Liu et al., 2015).
While the role of Hh pathway in EMT induction in CC has
already been demonstrated by Ruiz i Altaba and other groups
(Varnat et al., 2009; Wang et al., 2012; Liu et al., 2015), our
study firstly described the maintenance of an invasive “EMT like
state” by an autocrine secretion of Hh ligands in CC cell lines.
This cellular mechanism may play a role in promoting cellular
invasion and metastatic spreading of CC to the liver, consistently
with our previous findings on tumor-stroma interactions in liver
neoplasms (Magistri et al., 2013). The impact of Hh pathway
on CC tumorigenesis has been recently questioned in mouse
models (Gerling et al., 2016; Lee J. J. et al., 2016). Using
different experimental systems such as the AOM/DSS model
of colitis-associated CC, it was demonstrated that Hh signaling
is downregulated in CC, and that Hh pathway inhibition may
intensify colon inflammation (colitis) in mice, thus promoting
tumorigenesis.
Conversely, other recent studies linked the same pathway
activation to pro-tumor effects and to the acquisition of a cancer
stem-like behavior (Kangwan et al., 2016; Wang et al., 2016).
Finally, it has been demonstrated that Hh active pathway
may hamper tumor immunosurveillance (for example
downregulating MHC1 expression in epithelial tumor cells),
inhibiting the immune response against the tumor (Otsuka et al.,
2015; Hanna and Shevde, 2016). Therefore, the interpretation of
in vivomodels is so far extremely challenging.
In conclusion, our in vitro study established a causal link
between constitutive Hh activity and the acquisition of pro-
invasive, mesenchymal-like properties in CC cell lines.
When looking for a possible translational relevance of these
discoveries, one may hypothesize that subsets of colorectal
tumors endowed with abnormal Hh signaling due to mutations,
such as a recently reported PTCH1 loss-of-function mutation
(Chung and Bunz, 2013), that may not have been represented in
the cohorts previously treated with Hh inhibitors (Berlin et al.,
2013), may benefit from drugs inhibiting Hh activity such as
GDC-0449.
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